Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ifosfamide + pegaspargase + gemcitabine + cisplatin + dexamethasone
- Development stage
- Phase 2
- Lead developer
- Chinese Academy of Medical Sciences
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
The IPGDP regimen is a five-drug combination chemotherapy protocol consisting of ifosfamide, pegaspargase, gemcitabine, cisplatin, and dexamethasone. It is being developed and evaluated by the Chinese Academy of Medical Sciences for the treatment of extranodal natural killer/T-cell lymphoma (ENKL), nasal type. This aggressive malignancy is strongly associated with Epstein-Barr virus and often exhibits multidrug resistance. The IPGDP regimen aims to overcome this resistance by combining agents with distinct mechanisms: gemcitabine (a pyrimidine antimetabolite), ifosfamide (an alkylating agent), cisplatin (a platinum-based DNA crosslinker), pegaspargase (an enzyme that depletes L-asparagine), and dexamethasone (a corticosteroid). The regimen is currently in Phase II clinical trials (NCT02560441), where it is being tested in combination with radiotherapy for early-stage disease and as a standalone therapy for advanced or relapsed/refractory ENKL.
- Other names
- IPGDP regimen
02
Targets
DNADNA polymerase familyGR (Glucocorticoid receptor)RNR (Ribonucleotide reductase)
Beyond the preview
Go deeper on ifosfamide + pegaspargase + gemcitabine + cisplatin + dexamethasone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ifosfamide + pegaspargase + gemcitabine + cisplatin + dexamethasone.